📄
DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing.
active
📄 Paper Details
DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing.
Li Y, Xu J, Lu Y, Bian H, Yang L, Wu H, Zhang X, Zhang B, Xiong M, Chang Y
Abstract
1. Cell Metab. 2021 Oct 5;33(10):2004-2020.e9. doi: 10.1016/j.cmet.2021.09.008. DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing. Li Y(1), Xu J(2), Lu Y(2), Bian H(3), Yang L(1), Wu H(1), Zhang X(2), Zhang B(2), Xiong M(4), Chang Y(5), Tang J(4), Yang F(4), Zhao L(2), Li J(5), Gao X(3), Xia M(6), Tan M(7), Li J(8). Author information: (1)State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Acade...
▸Metadata
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
5%
Debates
0
Incoming
1
Outgoing
1
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.